Ovarian Hyperstimulation Syndrome: all 62 studies

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Real-world Evidence on Follitropin Delta Individual DosingRecruitingNCT05173597
• The Letrozole Administration During Luteal PhaseNot yet recruitingNCT02686151Phase 3
• Low-dose Gonal-f® in Ovulation InductionTerminatedNCT01871532Phase 4Results posted
• Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSSCompletedNCT01815138Phase 4Results posted
• Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte MaturationTerminatedNCT01606709Phase 4Results posted
• The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte DonorsCompletedNCT00867659Not applicableResults posted
• Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist CyclesCompletedNCT00627406Phase 4Results posted
• Myo-Inositol for Ovarian Stimulation and ICSI Outcomes in Women With PCOSCompletedNCT07779850Not applicable
• Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With DiosminCompletedNCT06333691Not applicable
• Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation SyndromeActive, not recruitingNCT05638529Phase 4
• Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement TherapyCompletedNCT05588635
• Freeze All Strategy Versus Fresh Embryo Transfer After GnRH Analogue TriggerCompletedNCT05362734
• Ovarian Hyperstimulation Syndrome Using Calcium InfusionStatus unknownNCT05198128Not applicable
• Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High RespondersStatus unknownNCT04797338Phase 4
• Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid ResponseCompletedNCT04351126Phase 2
• Coasting Versus Antagonist Protocol in Patients at High Risk of OHSSCompletedNCT03996434Phase 4
• The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian SyndromeCompletedNCT03876145Not applicable
• Montelukast for Prevention & Treatment of OHSSSuspendedNCT03794037Phase 2
• Preventive Application of GnRH Antagonist on Early OHSSStatus unknownNCT03188471Phase 4
• Comparison of Clinical Outcomes Between IVM and Minimal Stimulation IVF in Patients With PCOSStatus unknownNCT03134482Not applicable
• Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ETStatus unknownNCT03071172Phase 3
• Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation SyndromeStatus unknownNCT02846493Phase 2
• Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSSStatus unknownNCT02827656Not applicable
• Ovarian Hyperstimulation Syndrome in Patients Triggered by GnRH Agonist for Excessive Follicular ResponseTerminatedNCT02701452Not applicable
• Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSSCompletedNCT02670304Phase 4
• The Influence of Timing of Cabergoline Initiation on Prevention of OHSSStatus unknownNCT02620605Phase 3
• Medical Assistance for the Procreation and Risk of Thrombosis.TerminatedNCT02610608
• Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)Status unknownNCT02392520Not applicable
• Monitoring the Early Follicular Phase With Androstenedione in Low-dose Step-up Ovulation Induction in High RespondersStatus unknownNCT02329483
• Response of VEGF and AT-II to HCG in PCOSCompletedNCT02265861Early Phase 1
• Corifollitropin Alfa Application in PCOS PatientsStatus unknownNCT02215135Phase 4
• Study of Serum Levels of Oxidative Stress Markers in Ovarian Hyperstimulation PatientsStatus unknownNCT02202278
• Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSSCompletedNCT02200952
• Long Acting GnRH Antagonist in PCOS Women Undergoing IVFStatus unknownNCT02084940
• Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation SyndromeStatus unknownNCT02022241Not applicable
• Dual Trigger to Reduce Ovarian Hyperstimulation SyndromeStatus unknownNCT02022228Not applicable
• The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive OutcomesWithdrawnNCT01979341Not applicable
• Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?TerminatedNCT01714648Phase 4
• Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.CompletedNCT01703728
• Ovarian Hyperstimulation Syndrome and CabergolineCompletedNCT01569256Not applicable
• Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS BiomarkersCompletedNCT01535859Phase 3
• Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome PreventionCompletedNCT01530490Early Phase 1
• Endometrial Receptivity After GnRH Agonist TriggeringCompletedNCT01500863Phase 4
• Double GnRH Antagonist Daily Dose in Hyperresponding IVF/ICSI Cycles May Prevent the OHSSCompletedNCT01477970
• Calcium for Prevention of Ovarian Hyperstimulation SyndromeCompletedNCT01427335Phase 3
• GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation SyndromeCompletedNCT01268761Phase 3
• A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin αCompletedNCT01111084
• Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)WithdrawnNCT01109888Phase 1/2
• An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM PenTerminatedNCT01080729
• Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation SyndromeCompletedNCT01014104Phase 1/2
• Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) ProgramCompletedNCT01009567Phase 1/2
• Ovarian Hyperstimulation Syndrome (OHSS) Prevention With AgonistCompletedNCT00835523
• Short Versus Long Protocol for IVF and IVF+ICSICompletedNCT00756028Phase 4
• Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation SyndromeCompletedNCT00665041Phase 2
• The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation SyndromeWithdrawnNCT00617864Not applicable
• In Vitro Maturation of Immature OocytesCompletedNCT00480337Not applicable
• Cabergoline Reduces OHSSCompletedNCT00440258Phase 3
• Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS PatientsStatus unknownNCT00417144Phase 4
• Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.WithdrawnNCT00365027Not applicable
• The Use of GnRH Agonist Trigger in the Prevention of OHSSCompletedNCT00349258Phase 4
• Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of QuinagolideCompletedNCT00329693Phase 2
• 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists"Status unknownNCT00119925Not applicable

← Ovarian Hyperstimulation Syndrome overview